Akebia Therapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
AKBA Nasdaq 2834 www.akebia.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Akebia Therapeutics, Inc.

Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum - Oct 7th, 2026 6:00 am
Akebia Therapeutics Announces Late-Breaking VOICE Trial Presentation and Posters on Akebia’s Rare Kidney Pipeline at ASN Kidney Week 2026 - Oct 6th, 2026 6:00 am
SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors - Sep 22nd, 2026 6:00 am
SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development - Sep 15th, 2026 6:00 am
Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases - Sep 14th, 2026 6:00 am
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sep 1st, 2026 2:05 pm
Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston - Sep 1st, 2026 6:00 am
Akebia Therapeutics Inc (AKBA) (Q2 2026) Earnings Call Highlights: Vafseo Surges 60% as VOICE ... - Aug 5th, 2026 11:10 pm
Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates - Aug 5th, 2026 4:10 pm
Akebia Therapeutics Q2 Earnings Call Highlights - Aug 5th, 2026 4:03 pm
Akebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights - Aug 5th, 2026 2:05 pm
Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases - Aug 3rd, 2026 6:00 am
Akebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights - Jul 29th, 2026 6:00 am
Akebia Therapeutics, Inc. (AKBA) Strengthens Vafseo Patent Protection Through 2036 - Jun 30th, 2026 7:10 am
U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA - Jun 30th, 2026 6:00 am
Akebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio - Jun 10th, 2026 6:00 am
Akebia Therapeutics Sees Vafseo Uptake Rising as Access and Pipeline Milestones Near - Jun 4th, 2026 6:05 pm